Novo Nordisk’s next-generation weight-loss drug CagriSema
Dec 20, 2024 · Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t …
Novo Nordisk’s New Obesity Pill Beats Wegovy In Early Trial - Forbes
Sep 11, 2024 · Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection …
Novo Nordisk next-gen shot shows 22% weight loss in early …
In December, Novo said its CagriSema drug, which is far more advanced in development than amycretin, led to 22.7% weight loss after 68 weeks, below the 25% the company had expected.
Novo Nordisk Sinks on Disappointing Trial Results for Next Gen Weight …
Dec 20, 2024 · Novo Nordisk said Friday that in the study of just over 3,400 patients, its new injectable weight loss drug CagriSema met its primary goal, with an average weight loss of …
Novo Nordisk's next-gen obesity treatment hits target in early …
6 days ago · Novo said that patients on a high dose of the injectable form of the drug, called amycretin, lost 22% of their weight after 36 weeks, when analyzing the effects if all people …
Novo Rebounds as Next-Gen Obesity Drug Elicits up to 22% Weight Loss
6 days ago · Novo Nordisk unveiled topline Phase Ib/IIa data Friday for its next-generation obesity treatment amycretin, which elicited up to 22% weight-loss in adults with overweight or obesity.. …
Daily pill cuts body weight by up to 13% after 3 months in
Sep 10, 2024 · A daily weight loss pill from Novo Nordisk was shown to lower body weight by up to 13% after three months in a Phase 1 clinical trial, according to findings presented Tuesday …
Novo’s latest obesity pill spurs major weight loss in small trial
Mar 7, 2024 · An experimental pill developed by Novo Nordisk helped obese people lose 13% of their body weight after three months of treatment in a small clinical trial, the company said …
Weight loss: Amycretin pill may be more effective than semaglutide
Sep 12, 2024 · Early findings from a phase 1 clinical trial first announced by the Danish company Novo Nordisk in March 2024, show that amycretin — an experimental drug they have …
Novo Nordisk's Wegovy weight loss drug wins UK approval for …
Jul 23, 2024 · The U.K.'s health regulator on Tuesday approved the use of Novo Nordisk's Wegovy drug to reduce the risk of obese adults suffering from serious heart problems or strokes.